EA027853B1 - Синтетические миметики апелина для лечения сердечной недостаточности - Google Patents
Синтетические миметики апелина для лечения сердечной недостаточности Download PDFInfo
- Publication number
- EA027853B1 EA027853B1 EA201491433A EA201491433A EA027853B1 EA 027853 B1 EA027853 B1 EA 027853B1 EA 201491433 A EA201491433 A EA 201491433A EA 201491433 A EA201491433 A EA 201491433A EA 027853 B1 EA027853 B1 EA 027853B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- polypeptide
- amide
- salt
- ester
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0057—Pumps therefor
- A61M16/0066—Blowers or centrifugal pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261591557P | 2012-01-27 | 2012-01-27 | |
US201261717760P | 2012-10-24 | 2012-10-24 | |
US201261731697P | 2012-11-30 | 2012-11-30 | |
PCT/IB2013/050666 WO2013111110A2 (en) | 2012-01-27 | 2013-01-25 | Synthetic apelin mimetics for the treatment of heart failure |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201491433A1 EA201491433A1 (ru) | 2014-12-30 |
EA027853B1 true EA027853B1 (ru) | 2017-09-29 |
Family
ID=47997598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201491433A EA027853B1 (ru) | 2012-01-27 | 2013-01-25 | Синтетические миметики апелина для лечения сердечной недостаточности |
Country Status (42)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2697515C2 (ru) * | 2014-03-25 | 2019-08-15 | Лантхиопеп Б.В. | Циклические аналоги апелина |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
UY35144A (es) * | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
US8921307B2 (en) * | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
IN2015DN02913A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 2012-11-30 | 2015-09-18 | Novartis Ag | |
WO2014099984A1 (en) * | 2012-12-20 | 2014-06-26 | Amgen Inc. | Apj receptor agonists and uses thereof |
KR20150127596A (ko) | 2013-03-14 | 2015-11-17 | 리제너론 파아마슈티컬스, 인크. | 아펠린 융합 단백질 및 이들의 용도 |
EP3024847A1 (en) * | 2013-07-25 | 2016-06-01 | Novartis AG | Disulfide cyclic polypeptides for the treatment of heart failure |
TW201518323A (zh) | 2013-07-25 | 2015-05-16 | Novartis Ag | 合成apelin多肽之生物結合物 |
EP3024846A1 (en) * | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic apelin derivatives for the treatment of heart failure |
PE20160878A1 (es) | 2013-07-25 | 2016-09-08 | Novartis Ag | Polipeptidos ciclicos para el tratamiento de la insuficiencia cardiaca |
UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
JP6483117B2 (ja) | 2013-11-20 | 2019-03-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Aplnrモジュレーター及びその使用 |
EA201691075A1 (ru) * | 2013-11-26 | 2016-09-30 | Новартис Аг | Способы оксимной конъюгации с кетон-модифицированными полипептидами |
WO2015089137A1 (en) | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
GB201407532D0 (en) * | 2014-04-29 | 2014-06-11 | Univ Ulster | Apelin analogues |
CN106536560B (zh) * | 2014-05-23 | 2021-03-09 | 诺华股份有限公司 | 从含二硫化物的蛋白质制备缀合物的方法 |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
SG11201609706VA (en) | 2014-06-23 | 2017-01-27 | Novartis Ag | Site specific protein modifications |
WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
WO2016116842A1 (en) * | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
EP3273981B1 (en) * | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of diabetes |
JP6356364B1 (ja) | 2015-05-20 | 2018-07-11 | アムジエン・インコーポレーテツド | Apj受容体のトリアゾールアゴニスト |
JP7063813B2 (ja) | 2016-02-15 | 2022-05-09 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 術後認知機能障害の処置のための方法及び医薬組成物 |
EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
US11400049B2 (en) | 2016-10-19 | 2022-08-02 | Avive, Inc. | Pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases |
EP3541805B1 (en) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
TW201920234A (zh) | 2017-09-11 | 2019-06-01 | 美商領導醫療有限公司 | 類鴉片促效劑肽及其用途 |
US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
US11807624B2 (en) | 2018-05-01 | 2023-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the APJ receptor |
CA3109082A1 (en) | 2018-08-16 | 2020-02-20 | Isolere Bio, Inc. | Genetically encoded polypeptide for affinity capture and purification of biologics |
AU2019378907A1 (en) | 2018-11-14 | 2021-06-03 | Altavant Sciences Gmbh | A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (TPH1) for treating diseases or disorders associated with peripheral serotonin |
CN112007027B (zh) * | 2020-09-14 | 2022-07-15 | 长春金赛药业有限责任公司 | 含酯基芳香丙酰胺类化合物及其代谢产物在制备治疗心衰药物中的应用 |
CN119101143A (zh) * | 2023-05-31 | 2024-12-10 | 浙江大学 | 一种G蛋白偏向的apelin-13多肽突变体及应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0630405T3 (da) | 1992-11-17 | 1999-01-04 | Icos Corp | Hidtil ukendt 7-transmembranreceptor benævnt V28 |
US6555339B1 (en) | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
ATE383424T1 (de) | 1997-12-24 | 2008-01-15 | Takeda Pharmaceutical | Polypeptide, deren herstellung und verwendung |
AU5759399A (en) | 1998-09-25 | 2000-04-17 | Takeda Chemical Industries Ltd. | Peptide derivative |
AU6002199A (en) | 1998-10-05 | 2000-04-26 | Takeda Chemical Industries Ltd. | Process for eliminating n-terminal methionine |
US7045532B2 (en) | 1999-04-30 | 2006-05-16 | Millennium Pharmaceuticals, Inc. | ACE-2 modulating compounds and methods of use thereof |
WO2001070769A1 (fr) | 2000-03-23 | 2001-09-27 | Takeda Chemical Industries, Ltd. | Derive peptidique |
AU2001264937A1 (en) | 2000-05-23 | 2001-12-03 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the agtrl1 gene |
DK1485707T3 (da) | 2001-07-16 | 2009-05-11 | Caprotec Bioanalytics Gmbh | Indsamlingsforbindelser, samlinger deraf og fremgangsmåder til analyse af proteomet og komplekse sammensætninger |
WO2003063892A1 (fr) | 2002-01-29 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Utilisation d'apeline |
WO2004081198A2 (en) | 2003-03-12 | 2004-09-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for modulating angiogenesis with apelin compositions |
US7947280B2 (en) | 2003-05-22 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Apelin and uses thereof |
WO2005029066A2 (en) | 2003-05-22 | 2005-03-31 | Agilent Technologies, Inc. | Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof |
EP1520861A1 (en) | 2003-09-11 | 2005-04-06 | Aventis Pharma Deutschland GmbH | Test system for the identification of APJ receptor ligands |
WO2005106493A1 (en) | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj) |
EP1768951A4 (en) | 2004-06-17 | 2011-06-15 | Musc Found For Res Dev | NON-NATURAL AMINO ACIDS |
WO2006023893A2 (en) | 2004-08-23 | 2006-03-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for modulating angiogenesis and apoptosis with apelin compositions |
JP2008013436A (ja) | 2004-10-14 | 2008-01-24 | Kanazawa Univ | 血管形成促進剤 |
WO2006047558A2 (en) | 2004-10-26 | 2006-05-04 | The General Hospital Corporation | Methods for detecting a trial fibrillation and related conditions |
US20060159676A1 (en) | 2005-01-14 | 2006-07-20 | Krieg Paul A | Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
US8673848B2 (en) * | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
EP1876448A1 (en) | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones. |
US7736346B2 (en) | 2005-10-18 | 2010-06-15 | Biocardia, Inc. | Bio-interventional therapeutic treatments for cardiovascular diseases |
US20080031871A1 (en) | 2006-02-21 | 2008-02-07 | Allen Margaret L | Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene |
EP2017355A4 (en) | 2006-04-25 | 2010-01-06 | Univ Kyushu Nat Univ Corp | ASSOCIATED WITH ARTERIOSCLEROSIS DISEASE AND USE THEREOF |
WO2009033819A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
JP2010539058A (ja) | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのtrap−14 |
US20110123534A1 (en) | 2007-12-12 | 2011-05-26 | Erasmus University Medical Center Rotterdam | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
WO2009075566A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
KR20110091702A (ko) | 2008-11-04 | 2011-08-12 | 앵커 테라퓨틱스, 인코포레이티드 | Apj 수용체 화합물 |
WO2010115874A1 (en) | 2009-04-07 | 2010-10-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment and the diagnosis ofpulmonary arterial hypertension |
US20120277144A1 (en) | 2009-11-04 | 2012-11-01 | Henricus Johannes Duckers | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
CA2797033C (en) | 2010-04-22 | 2021-10-19 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
RU2457216C1 (ru) | 2010-12-21 | 2012-07-27 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) | Додекапептиды, обладающие кардиопротекторными свойствами |
WO2013106437A1 (en) | 2012-01-09 | 2013-07-18 | Anchor Therapeutics, Inc. | Apj receptor compounds |
EP3024846A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic apelin derivatives for the treatment of heart failure |
PE20160878A1 (es) | 2013-07-25 | 2016-09-08 | Novartis Ag | Polipeptidos ciclicos para el tratamiento de la insuficiencia cardiaca |
TW201518323A (zh) | 2013-07-25 | 2015-05-16 | Novartis Ag | 合成apelin多肽之生物結合物 |
EP3024847A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Disulfide cyclic polypeptides for the treatment of heart failure |
-
2013
- 2013-01-23 US US13/747,621 patent/US8673848B2/en active Active
- 2013-01-24 UY UY0001034593A patent/UY34593A/es not_active Application Discontinuation
- 2013-01-24 JO JOP/2013/0027A patent/JO3380B1/ar active
- 2013-01-25 BR BR112014018306A patent/BR112014018306A8/pt not_active IP Right Cessation
- 2013-01-25 DK DK13711953.3T patent/DK2807183T3/en active
- 2013-01-25 KR KR1020147023505A patent/KR102068370B1/ko not_active Expired - Fee Related
- 2013-01-25 PE PE2014001176A patent/PE20142194A1/es active IP Right Grant
- 2013-01-25 CN CN201380016261.6A patent/CN104220452B/zh not_active Expired - Fee Related
- 2013-01-25 UA UAA201408328A patent/UA116196C2/uk unknown
- 2013-01-25 CA CA2862240A patent/CA2862240A1/en active Pending
- 2013-01-25 ES ES13711953.3T patent/ES2670832T3/es active Active
- 2013-01-25 LT LTEP13711953.3T patent/LT2807183T/lt unknown
- 2013-01-25 RS RS20180546A patent/RS57200B1/sr unknown
- 2013-01-25 TW TW102103025A patent/TWI576356B/zh not_active IP Right Cessation
- 2013-01-25 NZ NZ627772A patent/NZ627772A/en not_active IP Right Cessation
- 2013-01-25 MY MYPI2014002154A patent/MY172268A/en unknown
- 2013-01-25 EA EA201491433A patent/EA027853B1/ru not_active IP Right Cessation
- 2013-01-25 AR ARP130100228A patent/AR089808A1/es unknown
- 2013-01-25 SG SG11201404369PA patent/SG11201404369PA/en unknown
- 2013-01-25 EP EP13711953.3A patent/EP2807183B1/en active Active
- 2013-01-25 HR HRP20180806TT patent/HRP20180806T1/hr unknown
- 2013-01-25 WO PCT/IB2013/050666 patent/WO2013111110A2/en active Application Filing
- 2013-01-25 PT PT137119533T patent/PT2807183T/pt unknown
- 2013-01-25 SI SI201330999T patent/SI2807183T1/en unknown
- 2013-01-25 AU AU2013213265A patent/AU2013213265C1/en not_active Ceased
- 2013-01-25 MX MX2014009085A patent/MX351569B/es active IP Right Grant
- 2013-01-25 CU CUP2014000097A patent/CU24266B1/xx unknown
- 2013-01-25 AP AP2014007846A patent/AP2014007846A0/xx unknown
- 2013-01-25 HU HUE13711953A patent/HUE039137T2/hu unknown
- 2013-01-25 KR KR1020197037887A patent/KR20200003229A/ko not_active Ceased
- 2013-01-25 TR TR2018/07309T patent/TR201807309T4/tr unknown
- 2013-01-25 JP JP2014553847A patent/JP6313222B2/ja not_active Expired - Fee Related
- 2013-01-25 PL PL13711953T patent/PL2807183T3/pl unknown
-
2014
- 2014-01-28 US US14/165,680 patent/US9067971B2/en active Active
- 2014-07-22 ZA ZA2014/05400A patent/ZA201405400B/en unknown
- 2014-07-23 TN TNP2014000318A patent/TN2014000318A1/fr unknown
- 2014-07-24 IL IL233792A patent/IL233792B/en active IP Right Grant
- 2014-07-25 GT GT201400166A patent/GT201400166A/es unknown
- 2014-07-25 PH PH12014501701A patent/PH12014501701A1/en unknown
- 2014-07-25 CL CL2014001994A patent/CL2014001994A1/es unknown
- 2014-07-28 CR CR20140364A patent/CR20140364A/es unknown
- 2014-07-31 CO CO14167109A patent/CO7020879A2/es unknown
- 2014-08-27 EC ECIEPI201416014A patent/ECSP14016014A/es unknown
-
2015
- 2015-05-18 US US14/714,914 patent/US9982017B2/en active Active
-
2017
- 2017-10-06 JP JP2017195815A patent/JP6595553B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-24 CY CY20181100556T patent/CY1120239T1/el unknown
Non-Patent Citations (5)
Title |
---|
ALEXANDRE MURZA, ALEXANDRE PARENT, ELIE BESSERER-OFFROY, HUGO TREMBLAY, FÉLIX KARADEREYE, NICOLAS BEAUDET, RICHARD LEDUC, PHILIPPE: "Elucidation of the Structure-Activity Relationships of Apelin: Influence of Unnatural Amino Acids on Binding, Signaling, and Plasma Stability", CHEMMEDCHEM, WILEY-VCH, vol. 7, no. 2, 6 February 2012 (2012-02-06), pages 318 - 325, XP055072892, ISSN: 18607179, DOI: 10.1002/cmdc.201100492 * |
JURI HAMADA, JUNKO KIMURA, JUNJI ISHIDA, TAKEO KOHDA, SETSUO MORISHITA, SHIGEYASU ICHIHARA, AKIYOSHI FUKAMIZU: "Evaluation of novel cyclic analogues of apelin.", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, D.A. SPANDIDOS, vol. 22, no. 4, 1 October 2008 (2008-10-01), pages 547 - 552, XP055072884, ISSN: 11073756 * |
M. V. SIDOROVA, A. A. AZ’MUKO, M. E. PAL’KEEVA, A. S. MOLOKOEDOV, V. N. BUSHUEV, S. N. DVORYANTSEV, V. S. SHULZHENKO, YU. A. PELOG: "Synthesis and cardioprotective properties of apelin-12 and its structural analogues", RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, M A I K NAUKA - INTERPERIODICA, RU, vol. 38, no. 1, 1 January 2012 (2012-01-01), RU, pages 40 - 51, XP002706051, ISSN: 1068-1620, DOI: 10.1134/S1068162012010177 * |
N. J. MAXIMILIAN MACALUSO, ROBERT C. GLEN: "Exploring the ‘RPRL’ Motif of Apelin-13 through Molecular Simulation and Biological Evaluation of Cyclic Peptide Analogues", CHEMMEDCHEM, WILEY-VCH, vol. 5, no. 8, 2 August 2010 (2010-08-02), pages 1247 - 1253, XP055072887, ISSN: 18607179, DOI: 10.1002/cmdc.201000061 * |
N. J. MAXIMILIAN MACALUSO, SARAH L. PITKIN, JANET J. MAGUIRE, ANTHONY P. DAVENPORT, ROBERT C. GLEN: "Discovery of a Competitive Apelin Receptor (APJ) Antagonist", CHEMMEDCHEM, WILEY-VCH, vol. 6, no. 6, 6 June 2011 (2011-06-06), pages 1017 - 1023, XP055072896, ISSN: 18607179, DOI: 10.1002/cmdc.201100069 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2697515C2 (ru) * | 2014-03-25 | 2019-08-15 | Лантхиопеп Б.В. | Циклические аналоги апелина |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA027853B1 (ru) | Синтетические миметики апелина для лечения сердечной недостаточности | |
US20240066132A1 (en) | Novel fatty acids and their use in conjugation to biomolecules | |
JP6505692B2 (ja) | 心不全治療のためのジスルフィド環状ポリペプチド | |
JP6501775B2 (ja) | 心不全治療用の環状ポリペプチド | |
ES2705323T3 (es) | Miméticos de apelina lineales sintéticos para el tratamiento de la insuficiencia cardíaca | |
JP6505691B2 (ja) | 心不全治療用の環状アペリン誘導体 | |
JP2016527249A (ja) | 合成アペリンポリペプチドのバイオコンジュゲート | |
TW201632197A (zh) | 具有改良半衰期之合成愛帕琳(apelin)脂肪酸結合物 | |
US10369187B2 (en) | Peptide regulators of JNK family kinases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KG |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM BY KZ |